1,324
Participants
Start Date
October 31, 2009
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
Glycopyrronium bromide
Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
Placebo
Placebo inhalation capsules were provided for use via a SDDPI
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Fairhope
Novartis Investigative Site, Glendale
Novartis Investigative Site, Los Angeles
Novartis Investigative Site, Walnut Creek
Novartis Investigative Site, Newark
Novartis Investigative Site, Port Orange
Novartis Investigative Site, Tamarac
Novartis Investigative Site, Topeka
Novartis Investigative Site, Madisonville
Novartis Investigative Site, Slidell
Novartis Investigative Site, Biddeford
Novartis Investigative Site, Pikesville
Novartis Investigative Site, Ann Arbor
Novartis Investigative Site, Livonia
Novartis Investigative Site, Minneapolis
Novartis Investigative Site, Kansas City
Novartis Investigative Site, Saint Charles
Novartis Investigative Site, Missoula
Novartis Investigative Site, Bellevue
Novartis Investigative Site, Omaha
Novartis Investigative Site, Reno
Novartis Investigative Site, New Brunswick
Novartis Investigative Site, Rochester
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Tulsa
Novartis Investigative Site, Lincoln
Novartis Investigative Site, Johnson City
Novartis Investigative Site, Corpus Christi
Novartis Investigative Site, McKinney
Novartis Investigative Site, San Antonio
Novartis Investigative Site, Richmond
Novartis Investigative Site, Daw Park SA
Novartis Investigative Site, Bridgewater
Novartis Investigative Site, Courtice
Novartis Investigative Site, Mississuaga
Novartis Investigative Site, North York
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Hamakita
Novartis Investigative Site, Himeji
Novartis Investigative Site, Hitachi
Novartis Investigative Site, Kishiwada
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Matsue
Novartis Investigative Site, Matsusaka
Novartis Investigative Site, Moriya
Novartis Investigative Site, Naka-gun
Novartis Investigative Site, Obihiro
Novartis Investigative Site, Osaka
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Ōtsu
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Tokyo
Novartis Investigative Site, Yabu
Novartis Investigative Site, Yonezawa
Novartis Investigative Site, Almelo
Novartis Investigative Site, Eindhoven
Novartis Investigative Site, Harderwijk
Novartis Investigative Site, Heerlen
Novartis Investigative Site, Zutphen
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Iași
Novartis Investigative Site, Timișoara
Novartis Investigative Site, Irkutsk
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Krasnodar
Novartis Investigative Site, Moscow
Novartis Investigative Site, Nizhny Novgorod
Novartis Investigative Site, Novosibirsk
Novartis Investigative Site, Sochy
Novartis Investigative Site, Stavropol
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Singapore
Novartis Investigative Site, Daegu
Novartis Investigative Site, Pusan
Novartis Investigative site, Seoul
Novartis Investigative Site, Alicante
Novartis Investigative Site, Badalona
Novartis Investigative Site, Canet de Mar
Novartis Investigative Site, Cáceres
Novartis Investigative Site, Centelles
Novartis Investigative Site, Valencia
Novartis Investigative Site, Altunizade
Novartis Investigative Site, Aydin
Novartis Investigative Site, Diyarbakır
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Kinikli/Denizli
Novartis Investigative Site, Mersin
Novartis Investigative Site, Soke/Aydin
Novartis Investigative Site, Yenisehir/Izmir
Lead Sponsor
Novartis
INDUSTRY